SCHEMBL5139301

SCHEMBL5139301

O=C1c2ccncc2C(=O)c2c(F)ccc(F)c21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.59
MAOB P27338 1/20 0.59
CDC25B P30305 1/20 0.57
SMN1; SMN2 Q16637 4/20 0.46
TP53 P04637 3/20 0.46
CYP3A4 P08684 3/20 0.46
MAPT P10636 3/20 0.46
CASP1 P29466 3/20 0.46
BLM P54132 3/20 0.46
CASP7 P55210 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
KDM4E B2RXH2 2/20 0.45
ECE1 P42892 1/20 0.39
MUS81 Q96NY9 1/20 0.39
CCNE2 O96020 1/20 0.38
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29642200 1.00 MAOA (0.59) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL7813936 0.90 MAOA (0.49) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL7819427 0.90 MAOA (0.49) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL7806728 0.90 CDC25B (0.56) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL7810488 0.86 MAPT (0.51) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL7810480 0.86 MAPT (0.51) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL29642348 0.81 ECE1 (0.65) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL29642192 0.81 ECE1 (0.65) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL28381205 0.81 ECE1 (0.65) MAOAMAOBCDC25BSMN1; SMN2TP53
SCHEMBL28378350 0.81 ECE1 (0.65) MAOAMAOBCDC25BSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0752857-B1 AN IMPROVED METHOD OF SYNTHESIS FOR 6,9-BIS (2-AMINOETHYL)AMINO]BENZO g]ISOQUINOLINE-5,10-DIONE AND ITS DIMALEATE SALT NOVUSPHARMA SPA (IT) 2001-07-25 EP claimed
US-5717099-A Method of synthesis for 6,9-bis((2-aminoethyl)amino)benzo g!isoquinoline-5,10-dione and its dimaleate salt BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1998-02-10 US claimed
EP-0752857-A1 AN IMPROVED METHOD OF SYNTHESIS FOR 6,9-BIS (2-AMINOETHYL)AMINO]BENZO g]ISOQUINOLINE-5,10-DIONE AND ITS DIMALEATE SALT BOEHRINGER MANNHEIM ITALIA S.p.A. (IT) 1997-01-15 EP claimed
WO-1995026189-A1 AN IMPROVED METHOD OF SYNTHESIS FOR 6,9-BIS[(2-AMINOETHYL)AMINO]BENZO[g]ISOQUINOLINE-5,10-DIONE AND ITS DIMALEATE SALT BOEHRINGER MANNHEIM ITALIA, S.P.A. (US) 1995-10-05 WO claimed
EP-0503537-A1 6,9 Bis(substituted-amino)benzo-[g]isoquinoline-5,10-diones THE UNIVERSITY OF VERMONT (US) 1992-09-16 EP claimed
CN-114685583-A Glycoside compounds, preparation method and application thereof 西格莱(苏州)生物医药有限公司 2022-07-01 CN disclosed
CN-110873765-B Detection method of pixantrone maleate related substance 北京凯莱天成医药科技有限公司 2022-05-17 CN disclosed
CN-110873765-A Detection method of pixantrone maleate related substance 北京凯莱天成医药科技有限公司 2020-03-10 CN disclosed
WO-2008103320-A1 METHODS OF TREATING OPHTHALMIC DISORDERS WITH ANTHRAQUINONES NOVACEA, INC. (US) 2008-08-28 WO disclosed
WO-2005097128-A1 1,4-BIS-N-OXIDE AZAANTHRACENEDIONES AND THE USE THEREOF NOVACEA, INC. (US) 2005-10-20 WO disclosed
US-20050222190-A1 1,4-bis-N-oxide azaanthracenediones and the use thereof CURD JOHN G 2005-10-06 US disclosed
EP-0752857-B1 AN IMPROVED METHOD OF SYNTHESIS FOR 6,9-BIS (2-AMINOETHYL)AMINO]BENZO g]ISOQUINOLINE-5,10-DIONE AND ITS DIMALEATE SALT NOVUSPHARMA SPA (IT) 2001-07-25 EP disclosed
EP-0662076-A1 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY THE UNIVERSITY OF VERMONT (US) 1995-07-12 EP disclosed
EP-0639183-A1 NITROGEN OXIDES OF AZA- AND DIAZA-ANTHRACENEDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1995-02-22 EP disclosed
WO-1994006795-A1 2-AMINOALKYL-5-AMINOALKYLAMINO SUBSTITUTED ISOQUINOINDAZOLE-6-(2H)-ONES WITH ANTITUMOUR ACTIVITY THE UNIVERSITY OF VERMONT (US) 1994-03-31 WO disclosed
EP-0575526-A4 1994-03-30 EP disclosed
EP-0575526-A1 6,9 BIS(SUBSTITUTED-AMINO)BENZO g]ISOQUINOLINE-5,10-DIONES THE UNIVERSITY OF VERMONT (US) 1993-12-29 EP disclosed
WO-1992015300-A1 6,9 BIS(SUBSTITUTED-AMINO)BENZO[g]ISOQUINOLINE-5,10-DIONES THE UNIVERSITY OF VERMONT (US) 1992-09-17 WO disclosed
WO-1992015566-A1 NITROGEN OXIDES OF AZA- AND DIAZA-ANTHRACENEDIONE DERIVATIVES AS ANTITUMOR AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1992-09-17 WO disclosed
EP-0503537-A1 6,9 Bis(substituted-amino)benzo-[g]isoquinoline-5,10-diones THE UNIVERSITY OF VERMONT (US) 1992-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222190-A1 1,4-bis-N-oxide azaanthracenediones and the use thereof CCND1, BRCA1, CDKN1A MAOA 967/4885MAOB 904/4885CDC25B 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.